“We have remained hopeful throughout our pancreatic cancer trials, and now with Fast Track designation, our optimism is further fueled. We believe with this designation, cancer metabolism is truly being propelled forward, with devimistat at the helm.” Read more . . .
The FDA has granted a Fast Track designation to devimistat (CPI-613) for the treatment of metastatic pancreatic cancer.1 “Pancreatic cancer is notoriously challenging to treat and long overdue for a new approach,” said Philip A. Philip, MD, PhD, FRCP, professor of Oncology at the Barbara Ann Karmanos Cancer Institute at Wayne State University, in a statement.